Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the
launch of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin2 Foam, 1%, of Mylan
Pharmaceuticals Inc.
According to IQVIA sales data for the 12-month period ending December 2024, the Evoclin Foam, 1% market achieved annual sales of approximately $5.8 million
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
